Down Syndrome, Alzheimer disease
Conditions
Brief summary
The primary efficacy variable of the study, at both measurement time points, will be the Standardized Uptake Value Ratio (SUVR) from images generated with 18F-PI-2620 (images will be obtained between 0-90 minutes post-administration; the cerebellum will be used as the reference region), as a measure of tau protein aggregates in the brain., In addition to efficacy data, adverse effects will be recorded during the 24 hours following administration.
Interventions
DRUG[18F]PI-2620
Sponsors
Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary efficacy variable of the study, at both measurement time points, will be the Standardized Uptake Value Ratio (SUVR) from images generated with 18F-PI-2620 (images will be obtained between 0-90 minutes post-administration; the cerebellum will be used as the reference region), as a measure of tau protein aggregates in the brain., In addition to efficacy data, adverse effects will be recorded during the 24 hours following administration. | — |
Countries
Spain
Outcome results
None listed